CVKD Cadrenal Therapeutics, Inc.

Fundamentals / CIK 0001937993 / USD

Cadrenal Therapeutics, Inc. reported $3.46M in total assets and a net loss of $10.10M through December 31, 2025 from SEC EDGAR filings.

Audited annual (10-K / 20-F) and quarterly (10-Q) statements parsed directly from SEC EDGAR CompanyFacts. Open CVKD in the Convexity terminal for live prices, valuation multiples, transcripts, and insider flow.

Annual revenue and net income

4 fiscal years (2022 to 2025), reported in USD.

$0$0$0-$12.38MFY 2022 Net Income: -$6.71M2022FY 2023 Net Income: -$8.36M2023FY 2024 Net Income: -$10.65M2024FY 2025 Net Income: -$13.24M2025

Financial statements and ratios

Reported in USD. Per-share figures and share counts are adjusted for stock splits from SEC filings.

Income Statement (Annual) · Reported in USD · Newest filing period first.

Income Statement Dec 31 Dec 31 Dec 31 Dec 31
Cost of Revenue -- -- $220K --
Research & Development $4.10M $4.21M $4.08M $393K
Total Operating Expenses $13.46M $10.96M $7.63M $2.70M
Operating Income -$13.46M -$10.96M -$7.63M -$2.70M
EBITDA -$13.45M -$10.96M -$7.63M -$2.70M
Interest Income $224K $309K $249K $21
Interest Expense -- -- $3.5K $40K
Net Income -$13.24M -$10.65M -$8.36M -$6.71M
Basic EPS -$6.64 -$8.73 -$9.29 -$12.75
Diluted EPS -$6.64 -$8.73 -$9.29 -$12.75
Basic Shares Outstanding 2.0M 1.2M 899.5K 526.0K
Diluted Shares Outstanding 2.0M 1.2M 899.5K 526.0K

Income Statement (Quarterly) · Reported in USD · Newest filing period first.

Income Statement 2026-09-30 2026-06-30 2026-03-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31
Research & Development $225K $705K $772K $666K $688K $1.08M $1.67M $1.54M
Total Operating Expenses $1.27M $3.34M $2.51M $3.07M $2.73M $3.73M $3.93M $4.28M
Operating Income -$1.27M -$3.34M -$2.51M -$3.07M -$2.73M -$3.73M -$3.93M -$4.28M
EBITDA -$1.26M -$3.34M -$2.51M -$3.06M -$2.73M -$3.73M -$3.92M -$4.28M
Interest Income $18K $18K $18K $26K $48K $67K $83K $91K
Net Income -$1.25M -$3.32M -$2.50M -$3.04M -$2.69M -$3.67M -$3.85M -$4.19M
Basic EPS -$0.31 -$1.14 -$1.04 -- -$1.31 -$1.87 -$2.09 --
Diluted EPS -$0.31 -$1.14 -$1.04 -- -$1.31 -$1.87 -$2.09 --
Basic Shares Outstanding 4.1M 2.9M 2.4M -- 2.0M 2.0M 1.8M --
Diluted Shares Outstanding 4.1M 2.9M 2.4M -- 2.0M 2.0M 1.8M --

Balance Sheet (Annual) · Reported in USD · Newest filing period first.

Balance Sheet Dec 31 Dec 31 Dec 31 Dec 31
Cash & Cash Equivalents $4.01M $10.02M $8.40M $33K
Cash & Short-Term Investments $4.01M $10.02M $8.40M $33K
Total Current Assets $4.32M $10.11M $8.49M $728K
Property, Plant & Equipment, Net $5.2K $6.9K $2.3K $1.0K
Other Non-Current Assets $2.2K $3.8K $3.8K $6.0K
Total Non-Current Assets $7.3K $11K $27K $51K
Total Assets $4.33M $10.12M $8.52M $778K
Accounts Payable $651K $1.50M $167K $405K
Short-Term Debt -- -- -- $597K
Total Current Liabilities $1.59M $2.68M $827K $1.33M
Total Non-Current Liabilities $0 $0 $0 $4.99M
Total Liabilities $1.59M $2.68M $827K $6.33M
Total Debt (incl. Leases) -- -- $21K $641K
Common Stock $2.3K $1.8K $868 $8.2K
Retained Earnings -$38.96M -$25.72M -$15.07M -$6.71M
Total Stockholders' Equity $2.74M $7.44M $7.69M -$5.55M
Total Equity $2.74M $7.44M $7.69M -$5.55M

Balance Sheet (Quarterly) · Reported in USD · Newest filing period first.

Balance Sheet 2026-09-30 2026-06-30 2026-03-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31
Cash & Cash Equivalents $3.06M $2.39M $2.31M $4.01M $3.86M $5.57M $7.34M $10.02M
Cash & Short-Term Investments $3.06M $2.39M $2.31M $4.01M $3.86M $5.57M $7.34M $10.02M
Total Current Assets $3.45M $5.58M $2.86M $4.32M $4.08M $5.97M $7.94M $10.11M
Property, Plant & Equipment, Net $2.3K $2.7K $4.6K $5.2K $5.7K $4.3K $4.7K $6.9K
Other Non-Current Assets $2.2K $2.2K $2.2K $2.2K $2.2K $2.2K $3.8K $3.8K
Total Non-Current Assets $4.4K $4.8K $6.8K $7.3K $7.9K $6.4K $8.5K $11K
Total Assets $3.46M $5.59M $2.86M $4.33M $4.09M $5.98M $7.95M $10.12M
Accounts Payable $469K $872K $825K $651K $614K $896K $1.28M $1.50M
Total Current Liabilities $551K $1.50M $1.06M $1.59M $1.35M $1.68M $1.84M $2.68M
Total Non-Current Liabilities $0 $0 $0 $0 $0 $0 $0 $0
Total Liabilities $551K $1.50M $1.06M $1.59M $1.35M $1.68M $1.84M $2.68M
Common Stock $4.1K $3.1K $2.5K $2.3K $2.1K $2.0K $1.9K $1.8K
Retained Earnings -$46.03M -$44.78M -$41.46M -$38.96M -$35.92M -$33.24M -$29.57M -$25.72M
Total Stockholders' Equity $2.90M $4.09M $1.80M $2.74M $2.73M $4.30M $6.11M $7.44M
Total Equity $2.90M $4.09M $1.80M $2.74M $2.73M $4.30M $6.11M $7.44M

Cash Flow Statement (Annual) · Reported in USD · Newest filing period first.

Cash Flow Statement Dec 31 Dec 31 Dec 31 Dec 31
Net Income -$13.24M -$10.65M -$8.36M -$6.71M
Depreciation & Amortization $6.9K $1.9K $2.0K $1.3K
Stock-Based Compensation $1.94M $1.42M $710K $928K
Change in Payables -$852K $1.34M -$238K $405K
Operating Cash Flow -$12.60M -$7.36M -$3.53M -$1.20M
Capital Expenditure -$5.1K -$6.5K -$3.3K -$2.3K
Free Cash Flow -$12.61M -$7.36M -$3.53M -$1.21M
Investing Cash Flow -$5.1K -$6.5K -$3.3K -$2.3K
Common Stock Issued $4.86M $5.14M -- $8.0K
Financing Cash Flow $6.60M $8.98M $11.90M $1.24M
Net Change in Cash -$6.01M $1.62M $8.37M $33K

Cash Flow Statement (Quarterly) · Reported in USD · Newest filing period first.

Cash Flow Statement 2026-09-30 2026-06-30 2026-03-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31
Net Income -$1.25M -$3.32M -$2.50M -$3.04M -$2.69M -$3.67M -$3.85M -$4.19M
Depreciation & Amortization $400 $504 $555 $555 $401 $401 $5.5K $407
Stock-Based Compensation $108K $672K $252K $325K $473K $593K $549K $763K
Change in Payables -$403K $47K $174K $37K -$281K -$383K -$224K $1.01M
Operating Cash Flow -$1.92M -$2.23M -$3.00M -$2.57M -$2.36M -$3.03M -$4.65M -$1.79M
Capital Expenditure -- -- -- $0 -$1.9K $0 -$3.3K --
Free Cash Flow -- -- -- -$2.57M -$2.36M -$3.03M -$4.65M --
Investing Cash Flow -- -- -- $0 -$1.9K $0 -$3.3K --
Common Stock Issued $0 $1.52M -$64K $846K $668K $3.43M -$85K --
Financing Cash Flow $2.58M $2.31M $1.30M $2.72M $648K $1.26M $1.97M $7.45M
Net Change in Cash $668K $80K -$1.70M $148K -$1.71M -$1.77M -$2.68M $5.65M

Margins, returns, leverage, liquidity, and year-over-year growth computed directly from SEC EDGAR statement levels. Multi-year figures show cumulative per-share growth.

Ratios & Growth Dec 31 Dec 31 Dec 31 Dec 31
Return on Equity (ROE) -483.3% -143.2% -108.6% --
Return on Assets (ROA) -305.9% -105.2% -98.1% -862.8%
Current Ratio 2.72x 3.77x 10.27x 0.55x
Quick Ratio 2.52x 3.73x 10.16x 0.02x
Debt to Equity -- -- 0.00x --

Quarterly margins, ROE, and ROA use trailing-twelve-month (TTM) flows summed across four contiguous quarters. Growth rates are true year-over-year comparisons against the same quarter a year earlier.

Ratios & Growth 2026-09-30 2026-06-30 2026-03-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31
Return on Equity (ROE) -347.9% -282.1% -661.5% -483.3% -526.0% -328.2% -209.9% -143.2%
Return on Assets (ROA) -292.4% -206.5% -415.4% -305.9% -351.9% -236.0% -161.4% -105.2%
Current Ratio 6.26x 3.73x 2.68x 2.72x 3.02x 3.56x 4.32x 3.77x
Quick Ratio 5.54x 1.60x 2.17x 2.52x 2.85x 3.32x 3.99x 3.73x
Source: SEC EDGAR CompanyFacts (CIK 0001937993) · from March 31, 2022 Data through September 30, 2026 · synced Nov 21, 2026, 05:09 UTC · Open in terminal